股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 金嗓子控股集團有限公司 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06896 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50, ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06896 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 739,302,000 | | 0 | | 739,302,000 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 739,302,000 | | 0 | | 739,302,000 | 致：香港交易及結算所有限公司 公司名稱: 金嗓子控股集團有限公司 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 FF301 FF301 致：香港交易及結算所有限公司 公司名稱: 金嗓子控股集團有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06896 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 5 ...

Financial Performance - The group's revenue decreased by approximately RMB 205.3 million or 39.1% to about RMB 319.2 million for the six months ended June 30, 2025[13]. - Gross profit fell by approximately RMB 145.5 million or 37.1% to about RMB 246.3 million for the same period[13]. - EBITDA decreased by approximately RMB 69.7 million or 35.6% to about RMB 125.9 million for the six months ended June 30, 2025[13]. - Profit attributable to equity holders decreased by approximately RMB 50.5 million or 37.6% to about RMB 83.7 million for the same period[13]. - Revenue for the six months ended June 30, 2025, was RMB 319,223,000, a decrease of 39.1% compared to RMB 524,517,000 for the same period in 2024[104]. - Gross profit for the same period was RMB 246,297,000, down 37.0% from RMB 391,830,000 in 2024[104]. - Net profit for the period was RMB 83,674,000, representing a 37.6% decrease compared to RMB 134,196,000 in 2024[104]. - Basic and diluted earnings per share were RMB 11.32, down from RMB 18.15 in the prior year[104]. - The net cash flow from operating activities for the six months ended June 30, 2025, was RMB 28,409 thousand, a significant decline of 88.0% compared to RMB 237,783 thousand in 2024[114]. Dividend and Shareholder Information - The board does not recommend the declaration of any interim dividend for the six months ended June 30, 2025[13]. - The company declared a final dividend of HKD 0.5 per share for the six months ended June 30, 2025, totaling RMB 338,663,000, down from RMB 403,765,000 for the same period in 2024[126]. - As of June 30, 2025, the company had a total of 739,302,000 issued shares[91]. - Mr. Zeng Yong holds 516,013,700 shares, representing approximately 69.79% of the total issued shares[91]. - Ms. Jiang Peizhen holds 58,937,400 shares, accounting for 7.97% of the total issued shares[91]. - The family trust holds 453,025,800 shares, which is approximately 61.28% of the total issued shares[98]. Market and Product Information - The flagship product, Jinsongzi throat lozenges (OTC), accounted for approximately 90.6% of the total revenue as of June 30, 2025[25]. - The Jinsongzi throat treasure series products contributed about 8.9% to the total revenue as of June 30, 2025[29]. - Other products, including Ginkgo biloba tablets and the new Jinsongzi intestinal treasure, represented approximately 0.5% of total revenue as of June 30, 2025[30]. - The company aims to maintain its leading position in the throat lozenge market while increasing its market share in the pharmaceutical and food sectors in China[45]. - The company is responding to the growing global pharmaceutical market, driven by an aging population and increased health awareness, which is expected to boost demand for throat-related products[42]. Research and Development - The company has developed 35 new products since 1994, with 8 classified as pharmaceuticals and 21 as food products[32]. - The Jinsongzi complex probiotics lozenges, developed in collaboration with Beijing Agricultural University, utilize nine patented strains to enhance health benefits[32]. - The company is focusing on R&D to maintain competitive advantages in the probiotics market, which is currently dominated by imported brands[33]. - The new production and R&D base in Liuzhou, Guangxi, spans approximately 60,000 square meters, enhancing production efficiency and product quality[47]. - The second phase of the new base is expected to cover about 50,000 square meters, focusing on the development of health-related products and high-tech R&D teams[47]. Financial Position and Assets - The group's current assets net value was approximately RMB 748.8 million as of June 30, 2025, down from RMB 1,055.7 million as of December 31, 2024[64]. - Interest-bearing bank loans and other borrowings totaled approximately RMB 684.0 million as of June 30, 2025, an increase of about RMB 257.1 million or 60.2% from RMB 426.9 million as of December 31, 2024[66]. - The group's asset-liability ratio increased from approximately 29.1% on December 31, 2024, to about 56.6%[68]. - Total assets less current liabilities as of June 30, 2025, were RMB 1,258,447,000, a decrease from RMB 1,550,693,000 at the end of 2024[108]. - Cash and cash equivalents decreased to RMB 1,042,414,000 from RMB 1,130,628,000 at the end of 2024[107]. Operational Efficiency - Selling and distribution expenses were approximately RMB 119.4 million, a decrease of about RMB 64.8 million or 35.2% from RMB 184.2 million for the same period in 2024[58]. - The company has established a comprehensive distribution network covering all provinces, autonomous regions, and municipalities in China, with most revenue derived from sales to distributors[38]. - The online sales channels, including the Tmall flagship store, have been expanded to include new product lines, enhancing consumer access[39]. - The company has established partnerships with 11 promoters to enhance local market knowledge and product promotion[41]. Compliance and Governance - The audit committee reviewed the unaudited interim consolidated financial statements for the six months ending June 30, 2025, and found the existing risk management and internal control systems to be effective and adequate[88]. - The company confirmed that all directors complied with the standard code of conduct regarding securities trading for the six months ending June 30, 2025[85]. - The company did not purchase, sell, or redeem any of its listed securities during the six months ending June 30, 2025[86]. - No stock options were granted, exercised, canceled, or lapsed under the stock option plan since its adoption[97]. Future Outlook - The group plans to continue strengthening its leading position in the throat lozenge market and expand its market share in China's pharmaceutical and food sectors in the second half of 2025[78]. - The company has committed to invest approximately RMB 32.4 million in the second phase of a new pharmaceutical production and R&D base in Liuzhou, Guangxi Zhuang Autonomous Region[76].

公司名稱: 金嗓子控股集團有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06896 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | 本月底法定 ...

Core Viewpoint - The increasing prevalence of throat diseases due to environmental pollution, lifestyle changes, and an aging population is driving the demand for throat traditional Chinese medicine (TCM), with the market expected to reach 7.4 billion yuan in 2024, reflecting a year-on-year growth of 7.49% [1][9]. Overview - Throat diseases are primarily caused by various factors such as wind-heat invasion and internal heat, leading to symptoms like sore throat and hoarseness. Throat TCM is made from traditional Chinese medicinal ingredients and is used to treat throat-related ailments, characterized by stable efficacy and minimal side effects [1][3]. Development History - The throat medicine industry in China began relatively late, with significant advancements in chronic pharyngitis research in the 1980s leading to the development of throat medications. The market was initially fragmented, but the introduction of products like Guangxi Jinsongzi's throat lozenges in 1995 marked a turning point, establishing a competitive landscape [4][5]. Market Policy - The Chinese government has implemented various policies to support the development of the TCM industry, creating a favorable environment for throat TCM growth. These include measures to enhance TCM regulation and promote innovation [5][6]. Industry Chain - The throat TCM industry consists of an upstream segment focused on medicinal herb cultivation, a midstream segment for manufacturing, and a downstream segment involving sales through medical institutions, pharmacies, and e-commerce platforms. The primary consumer groups include individuals who use their voices frequently and patients with chronic throat conditions [6][7][8]. Current Market Situation - The throat TCM market is experiencing rapid growth, with a projected sales figure of 7.4 billion yuan in 2024. Tablets represent the largest segment at 41.65%, followed by granules and pills [1][9]. Competitive Landscape - The throat TCM market is characterized by high concentration, with the top five companies holding over 50% market share in retail pharmacies. Guangxi Jinsongzi leads with a market share of 16.95% [10][11]. Key Companies - Guangxi Jinsongzi Group is a major player in the throat TCM market, with a projected revenue of 1.185 billion yuan in 2024 and a gross profit margin of 75.46% [12]. - Guilin Sanjin Pharmaceutical Co., Ltd. is another key player, with a projected revenue of 2.194 billion yuan in 2024 and a gross profit margin of 73.41% [12]. Future Trends - The throat TCM industry is expected to focus on improving the quality of raw materials and production processes to meet rising consumer demands for high-quality products. Additionally, there is potential for international market expansion, particularly in Southeast Asia, as awareness and acceptance of TCM grow [13].

Core Viewpoint - The company reported a significant decline in revenue and net profit for the first half of 2025, attributed to changes in industry conditions and adjustments in marketing strategies. Financial Performance - The company achieved revenue of 319 million yuan, a year-on-year decrease of 39.14% [2] - Net profit was 83.674 million yuan, down 37.65% year-on-year [2] - Basic loss per share was 11.32 cents [2] Market Conditions - The decline in revenue is primarily due to changes in industry conditions during the first half of 2025 [2] - Adjustments in the company's product marketing strategies led to a reduction in purchases by customers and distributors [2]

Core Viewpoint - The company, Jin Sang Zi (06896.HK), reported a significant decline in revenue and profit for the six months ending June 30, 2025, indicating financial challenges ahead [1] Financial Performance - The group's revenue decreased by approximately RMB 205.3 million or 39.1% to about RMB 319.2 million [1] - The earnings before interest, taxes, depreciation, and amortization (EBITDA) fell by around RMB 69.7 million or 35.6% to approximately RMB 125.9 million [1] - The profit attributable to equity holders decreased by about RMB 50.5 million or 37.6% to around RMB 83.7 million [1]

Core Viewpoint - The company reported a significant decline in revenue and net profit for the six months ending June 30, 2025, primarily due to changes in industry conditions and adjustments in marketing strategies [1] Financial Performance - The company achieved revenue of 319 million yuan, representing a year-on-year decrease of 39.14% [1] - Net profit was recorded at 83.67 million yuan, down 37.65% compared to the previous year [1] - Basic loss per share was reported at 11.32 cents [1] Market Conditions - The decline in revenue is attributed to changes in the industry landscape during the first half of 2025 [1] - Adjustments in the company's product marketing strategies led to a reduction in purchases by customers and distributors in the first half of 2025 [1]

Financial Performance - The group's revenue decreased by approximately RMB 205.3 million or 39.1% to about RMB 319.2 million for the six months ended June 30, 2025, compared to the same period in 2024[3]. - Gross profit fell by approximately RMB 145.5 million or 37.1% to about RMB 246.3 million for the same period[3]. - Profit before tax decreased by approximately RMB 69.7 million or 35.6% to about RMB 125.9 million[3]. - Profit attributable to equity holders of the company decreased by approximately RMB 50.5 million or 37.6% to about RMB 83.7 million[3]. - Total comprehensive income for the period was RMB 80.1 million, down from RMB 135.6 million in the previous year[5]. - The group's profit before tax for the six months ended June 30, 2025, was RMB 72,926,000, a decrease of 45% compared to RMB 132,687,000 for the same period in 2024[13]. - Net profit for the six months ended June 30, 2025, was approximately RMB 83.7 million, a decrease of about RMB 50.5 million or 37.6% from RMB 134.2 million in the same period of 2024, attributed to a decline in product sales[69]. Dividend and Shareholder Returns - The board of directors did not recommend the declaration of any interim dividend for the six months ended June 30, 2025[3]. - The group declared a final dividend of HKD 0.5 per ordinary share for the six months ended June 30, 2025, down from HKD 0.6 in 2024, totaling RMB 338,663,000 compared to RMB 403,765,000[18]. - The company did not declare any interim dividends for the six months ended June 30, 2025, consistent with the previous year[18]. - The board does not recommend declaring any interim dividend for the six months ended June 30, 2025[87]. Assets and Liabilities - Cash and cash equivalents decreased to RMB 1,042.4 million from RMB 1,130.6 million as of December 31, 2024[6]. - Trade receivables decreased significantly to RMB 243.2 million from RMB 420.6 million[6]. - The total assets less current liabilities amounted to RMB 1,258.4 million, down from RMB 1,550.7 million[7]. - The company's equity attributable to equity holders decreased to RMB 1,207.8 million from RMB 1,466.3 million[7]. - As of June 30, 2025, the company's current assets net value was approximately RMB 748.8 million, down from RMB 1,055.7 million as of December 31, 2024[70]. - Total interest-bearing bank loans and other borrowings increased to approximately RMB 684.0 million, up about RMB 257.1 million or 60.2% from RMB 426.9 million at the end of 2024[71]. - The debt-to-equity ratio increased from approximately 29.1% as of December 31, 2024, to about 56.6% as of June 30, 2025[73]. Revenue Sources - The group's flagship product, Jin Sangzi throat lozenges (OTC), accounted for approximately 90.6% of total revenue for the six months ended June 30, 2025[38]. - Revenue from the sales of Jin Sangzi throat lozenges (OTC) was approximately RMB 289.1 million, down by RMB 189.3 million or 39.6% from RMB 478.4 million in the previous year[55]. - The Jin Sangzi throat treasure series products contributed about 8.9% to total revenue for the same period, with new export markets including South Korea and Peru[40]. - Other products, including Ginkgo biloba tablets and the new Jin Sangzi intestinal treasure, represented about 0.5% of total revenue[41]. Research and Development - The group has developed 35 new products since 1994, obtaining production licenses for 8 pharmaceutical products, 21 food products, 1 health food product, and 1 medical device[42]. - The group is collaborating with Beijing Agricultural University on the development of a new composite probiotic lozenge, which has obtained six patents[41]. - The company launched the Jin Sang Zi compound probiotic lozenges in collaboration with Beijing Agricultural University, utilizing proprietary strains and securing six patents[43]. - By 2025, the Jin Sang Zi compound probiotic series will be upgraded to include nine patented strains, significantly enhancing its efficacy in areas such as immune regulation and blood sugar control[43]. - The group has a strong focus on R&D, collaborating with hospitals and research institutions to enhance product development[42]. Market Position and Strategy - The company aims to strengthen its brand recognition and image in China through increased advertising and targeted marketing strategies[53]. - The company aims to strengthen its market position in the throat lozenge market and expand its market share in the pharmaceutical and food sectors in the second half of 2025[82]. - The company has successfully exported products to over 60 countries and regions, with new markets including South Korea and Peru added in early 2025[46]. - The company has established a flagship store on Tmall, introducing various new products including six flavors of Jin Sang Zi throat lozenges[48]. - The company has signed promotional agreements with 11 promoters to enhance local market penetration and feedback[49]. Operational Updates - The company plans to enhance its production capacity by constructing a new production base in Liuzhou, Guangxi, covering an area of approximately 60,000 square meters, which includes a research and development center and automated production lines[53]. - The company has selected a 48-acre site for the second phase of the Jin Sangzi new base, which is expected to have a built-up area of approximately 50,000 square meters, focusing on the development of health products[54]. - The construction of the food production plant and R&D center has completed above-ground construction and has commenced internal construction as of June 30, 2025[85]. - The total amount allocated for the construction of the food production plant and R&D center is HKD 177.4 million, with an unutilized balance of HKD 151.4 million as of June 30, 2025[84]. - The company has reallocated approximately HKD 37.997 million originally intended for establishing a Chinese herbal processing base to the construction of the food production plant and R&D center[84]. Governance and Compliance - The audit committee has reviewed the unaudited interim consolidated financial statements for the six months ended June 30, 2025, and found the existing risk management and internal control systems to be effective and adequate[92]. - The company has adopted a corporate governance code to ensure high standards of corporate governance and protect shareholder interests[88].